US 10,758,239

Application 15/358,483 · Granted Sep 1, 2020

Methods and devices for passive residual lung volume reduction and functional lung volume expansion

Estimated expiration

January 23, 2023

Expired 1398 days ago

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Sep 10, 2002
+ 20 years
Sep 10, 2022
PTA +830d
Dec 18, 2024
TD cap (US 9,533,116)
Jan 23, 2023
Final
Jan 23, 2023

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
November 22, 2016
Earliest effective filing
September 10, 2002
Issue date
September 1, 2020
PTA
+830 days
Base expiry (before PTA)
September 10, 2022

September 10, 2002 + 20 years = September 10, 2022 + 830 PTA days = December 18, 2024

  • Continuation of application 13/938,025, filed Jul 9, 2013, issued as US 9,533,116
  • Continuation of application 12/820,547, filed Jun 22, 2010, issued as US 8,496,006
  • Continuation-in-part of application 11/685,008, filed Mar 12, 2007
  • Continuation-in-part of application 11/296,951, filed Dec 7, 2005, issued as US 7,883,471
  • Continuation-in-part of application 10/241,733, filed Sep 10, 2002
  • Continuation-in-part of application 11/685,008, filed Mar 12, 2007
  • Continuation-in-part of application 11/296,951, filed Dec 7, 2005, issued as US 7,883,471
  • Continuation of application 12/820,547, filed Jun 22, 2010, issued as US 8,496,006
  • Continuation-in-part of application 11/685,008, filed Mar 12, 2007
  • Continuation-in-part of application 11/296,951, filed Dec 7, 2005, issued as US 7,883,471
  • PRO60/699,289 — Provisional — not used for base term
  • PRO60/696,940 — Provisional — not used for base term
  • PRO60/645,711 — Provisional — not used for base term
  • PRO60/318,539 — Provisional — not used for base term
  • PRO60/318,539 — Provisional — not used for base term
  • PRO60/699,289 — Provisional — not used for base term
  • PRO60/696,940 — Provisional — not used for base term
  • PRO60/645,711 — Provisional — not used for base term
  • PRO60/645,711 — Provisional — not used for base term
  • PRO60/696,940 — Provisional — not used for base term
  • PRO60/699,289 — Provisional — not used for base term
  • PRO60/645,711 — Provisional — not used for base term
  • PRO60/696,940 — Provisional — not used for base term
  • PRO60/699,289 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 1 filed

TD caps expiration to January 23, 2023 (earliest expiring referenced patent: US 9,533,116)

  • US 9,533,116· Application 13/938,025Capping patent

    Methods and devices for passive residual lung volume reduction and functional lung volume expansion

    Filing date
    Jul 9, 2013
    Earliest effective filing
    Sep 10, 2002
    Issue date
    Jan 3, 2017
    PTA
    +135 days
    Calculated expiration
    Jan 23, 2023

    Continuation of 12/820,547, filed Jun 22, 2010, issued as US 8,496,006

    Continuation-in-part of 11/685,008, filed Mar 12, 2007

    Continuation-in-part of 11/296,951, filed Dec 7, 2005, issued as US 7,883,471

    Continuation-in-part of 10/241,733, filed Sep 10, 2002

    Continuation-in-part of 11/685,008, filed Mar 12, 2007

    Continuation-in-part of 11/296,951, filed Dec 7, 2005, issued as US 7,883,471

    Sep 10, 2002 + 20y + 135d PTA = Jan 23, 2023

  • US 8,496,006· Application 12/820,547

    Methods and devices for passive residual lung volume reduction and functional lung volume expansion

    Filing date
    Jun 22, 2010
    Earliest effective filing
    Sep 10, 2002
    Issue date
    Jul 30, 2013
    PTA
    +356 days
    Calculated expiration
    Sep 1, 2023

    Continuation-in-part of 11/685,008, filed Mar 12, 2007

    Continuation-in-part of 11/296,951, filed Dec 7, 2005, issued as US 7,883,471

    Continuation-in-part of 10/241,733, filed Sep 10, 2002

    Sep 10, 2002 + 20y + 356d PTA = Sep 1, 2023

  • US 10,758,239· Application 15/358,483(from application 15/358,483)

    Methods and devices for passive residual lung volume reduction and functional lung volume expansion

    Filing date
    Nov 22, 2016
    Earliest effective filing
    Sep 10, 2002
    Issue date
    Sep 1, 2020
    PTA
    +830 days
    Calculated expiration
    Dec 18, 2024

    Continuation of 13/938,025, filed Jul 9, 2013, issued as US 9,533,116

    Continuation of 12/820,547, filed Jun 22, 2010, issued as US 8,496,006

    Continuation-in-part of 11/685,008, filed Mar 12, 2007

    Continuation-in-part of 11/296,951, filed Dec 7, 2005, issued as US 7,883,471

    Continuation-in-part of 10/241,733, filed Sep 10, 2002

    Continuation-in-part of 11/685,008, filed Mar 12, 2007

    Continuation-in-part of 11/296,951, filed Dec 7, 2005, issued as US 7,883,471

    Continuation of 12/820,547, filed Jun 22, 2010, issued as US 8,496,006

    Continuation-in-part of 11/685,008, filed Mar 12, 2007

    Continuation-in-part of 11/296,951, filed Dec 7, 2005, issued as US 7,883,471

    Sep 10, 2002 + 20y + 830d PTA = Dec 18, 2024

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 15/358,483 · US 10,758,239

PatentReply compiles the prosecution history behind US 10,758,239: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US10758239

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.